Diabetes is a major risk factor for severe COVID-19 and poor clinical outcomes duringhospitalization. However, little is known about the medium- and long-term metabolicconsequences of COVID-19 in people with diabetes after hospital discharge.The DMD-COV study is a prospective, multicenter observational cohort conducted inAlgeria. Its aim is to evaluate the cardio-metabolic outcomes of adult patients withdiabetes who were hospitalized for confirmed COVID-19 and survived the acute phase of theinfection.Adult patients with type 1 or type 2 diabetes will be included during hospitalization orwithin 30 days after hospital discharge. Participants will be followed for up to one yearafter discharge, with scheduled evaluations at baseline, 3 months, 6 months, and 12months.During follow-up, clinical, biological, and therapeutic data will be collected, includingglycemic control (HbA1c), body weight, lipid profile, kidney function, and diabetestreatments. The main outcome is the proportion of patients achieving their individualizedHbA1c target at 6 months and 12 months after hospitalization for COVID-19.The results of this study will help to better understand the long-term metabolic impactof COVID-19 in people with diabetes and to improve post-COVID diabetes management.
The DMD-COV study is a prospective, non-interventional, multicenter cohort study
conducted in Algeria. The study aims to describe the cardio-metabolic outcomes of adult
patients with diabetes following hospitalization for COVID-19.
Patients with type 1 or type 2 diabetes who were hospitalized for laboratory-confirmed
COVID-19 (PCR, serology, or antigen test) will be included during hospitalization or
within 30 days after discharge. The study does not interfere with routine clinical care,
and all therapeutic decisions are made according to usual medical practice.
Approximately 200 patients will be enrolled across multiple university hospital centers.
Participants will be followed for one year, with four scheduled visits: at baseline
(inclusion), 3 months, 6 months, and 12 months after hospital discharge.
Data collected during the study include demographic characteristics, diabetes history,
comorbidities, COVID-19 severity markers, duration of hospitalization, and treatments
received during the acute phase, including corticosteroids and anticoagulants. At each
follow-up visit, clinical parameters (weight, body mass index, waist circumference),
glycemic control (HbA1c, fasting plasma glucose), lipid profile, renal function, and
diabetes treatments will be recorded.
The primary outcome is glycemic control, assessed by the proportion of patients achieving
their individualized HbA1c target at 6 months and 12 months after hospitalization.
Secondary outcomes include changes in HbA1c over time, evolution of diabetes treatments,
weight changes, lipid profile, renal function, and identification of factors associated
with good glycemic control after COVID-19.
This study will provide valuable real-world data on the metabolic evolution of patients
with diabetes after COVID-19 and may contribute to optimizing long-term follow-up
strategies in this population.
Other: No intervention (observational study)
This is a non-interventional observational study. No experimental or therapeutic
intervention is assigned as part of the study protocol. All medical care and treatments
are provided according to routine clinical practice.
Inclusion Criteria:
- Age 18 years or older
- Diagnosis of type 1 or type 2 diabetes mellitus
- Hospitalization for laboratory-confirmed COVID-19
- Inclusion during hospitalization or within 30 days after hospital discharge
- Signed informed consent
Exclusion Criteria:
- Age under 18 years
- Absence of diabetes mellitus
- Refusal or inability to provide informed consent
Djillali Belkhenchir Public Hospital (formerly Birtraria)
Algiers, El Biar, Algeria
Not Provided